Characterising patients with COPD by baseline short-acting β2-agonist (SABA) use: a post hoc analysis of the EMAX trial
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI